Research Article, J Liver Dis Transplant Vol: 5 Issue: 1
Analysis of Pretreatment Predictors of a Virological Response to Interferon Therapy in Co-infected Patients of Hepatitis C and B
|Maleha Asim1*, Amir Rashid2, Asifa Majeed2 and Suhail Razak2|
|1Department of Biochemistry, Foundation University Medical College, Islamabad, Pakistan|
|2Department of Biochemistry and Molecular Biology, Army Medical College, National University of Sciences and Technology, Rawalpindi, Pakistan|
|Corresponding author : Maleha Asim
Department of Biochemistry, University Medical College, Islamabad, Pakistan
E-mail: [email protected]
|Received: November 09, 2015 Accepted: March 10, 2016 Published: March 16, 2016|
|Citation: Asim M, Rashid A, Majeed A, Razak S (2016) Analysis of Pretreatment Predictors of a Virological Response to Interferon Therapy in Co-infected Patients of Hepatitis C and B. J Liver: Dis Transplant 5:1. doi:10.4172/2325-9612.1000134|
Background: Several pretreatment parameters are strongly associated with sustained virological response rate (SVR) in HCV/ HBV co-infected patients.
Methods: We identified 104 HCV/HBV co-infected patients (69 males and 35 females) who were treated with standard interferon-alfa-2a or pegylated-IFN-alfa-2b by using electronic query. Data analysis includes their age, gender, clinical, hierological and histological parameters.Patients were divided into two groups of interferon responders (negative HCV RNA level) and non-responders (patients with positive HCV-RNA levels). Multivariate regression analysis was used to assess the effect of pre-treatment variables and therapy regime on sustained virological rate (SVR) in both groups.
Results: The pretreatment parameters significantly associated with sustained virological response to interferon therapy were low levels of serum ALT (p=0.002), HCV-RNA (?4×105 IU/ml) (p=0.038), HBVDNA(?2×104 IU/ml) (p=0.002), HCV genotype-3 (p=0.025) and IL- 28B CC genotype (p=0.049). As for histological factors, normal to minimal change in liver biopsy was found considerably associated with therapy response (p=0.024). Significant advantage of peginterferon plus ribavirin was also observed for SVR (p=0.004).Post-treatment HBV-DNA clearance was observed in 22% of 104 co-infected patients.
Conclusion: Pretreatment parameters are closely related with better response to therapy. Peg-interferon and ribavirin in combination is an effective regime significantly associated with SVR in HCV/HBV co-infected patients.